Skip to main content

Biomarkers in Lewy Body Dementia


The goal of this longitudinal study is to discover better biomarkers, measures of what's happening inside the living body, for diagnosis and treatment of Lewy body dementia.

Minimum Age Maximum Age Gender Healthy Volunteers
65 Years N/A All No
March 31, 2024

  • Diagnosed with dementia with Lewy bodies or with Parkinson's disease with cognitive change
  • Speak English or Spanish

  • None given

Participants will complete 4 to 5 visits over 3.5 years, including neurological evaluations and collection of blood, urine, and cerebrospinal fluid samples. Researchers will use this information, along with previously collected brain samples, to better understand how the contribution of co-existing Alzheimers disease may affect the diagnosis and clinical course of Lewy body disorders and to develop biomarkers specific to Lewy body dementia.

Name City State Zip Status Primary Contact
Columbia University Medical Center
New York New York 10032 Recruiting Helen Mejia-Santana

The U.S. National Institutes of Health

Name Role Affiliation
Karen Marder, MD Principal Investigator Columbia University
Lawrence Honig, MD, PhD Principal Investigator Columbia University

Name Phone Email
Helen Mejia-Santana 212-305-9183
Martha Orbe-Reilly, MD 212-305-8873